Literature DB >> 25163630

Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population.

R Salazar-González1, R Gómez, S Romano-Moreno, S Medellín-Garibay, A Núñez-Ruíz, M Magaña-Aquino, R C Milán-Segovia, D P Portales-Pérez.   

Abstract

Arylamine N-acetyltransferase 2 (NAT2) metabolizes isoniazid (INH) and Single Nucleotide Polymorphisms (SNP) responsible for its activity has been reported. The aim of this study in the Mexican mestizo population was to evaluate NAT2 expression at the protein level in immune cells, as well as the distribution and frequency of six NAT2 SNPs and their association with anti-TB therapy, by measuring the plasma levels of INH and Acetyl-INH (AcINH). We performed genotyping assays of NAT2 SNPs in 40 TB patients and 121 healthy volunteers by real-time PCR. A method for detecting NAT2 in immune cells using flow cytometry was developed. Plasma concentrations of INH and AcINH were obtained by HPLC in TB patients and the Metabolic Ratio (MR) was calculated. The phenotypes obtained in the healthy volunteers were as follows; 18.87 % of subjects had the rapid acetylator phenotype, 45.45 % had the intermediate phenotype and 39.66 % exhibited the slow acetylator phenotype. In the TB patient group, 35 % of patients had the rapid acetylator phenotype, 32.5 % were intermediate and 32.5 % showed the slow acetylator phenotype. A higher expression level of NAT2 in innate immune cells from TB patients compared to those from healthy volunteers was detected (P < 0.013). In TB patients the MR showed a bimodal distribution with an antimode of 0.7, which was used as a threshold value for acetylator classification. A high correspondence between the rapid and slow acetylator phenotype with MR was demonstrated. In conclusion, the 282C>T, 341T>C, 481C>T, 590G>A, 803A>G, 857G>A SNPs of NAT2 gene provides accurate for prediction of the acetylator phenotype in Mexican mestizo population. A statistical difference was found in frequency of rapid metabolizer phenotype, which was higher in TB patients. In addition, the expression of NAT2 protein in immune cells can lead to further studies related to its functional role in the innate immune response against M. tuberculosis and other xenobiotics metabolized by this enzyme.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25163630     DOI: 10.1007/s11033-014-3677-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  44 in total

Review 1.  Polymorphism in human N-acetyltransferase--the case of the missing allele.

Authors:  E Sime; D Hickman
Journal:  Trends Pharmacol Sci       Date:  1991-06       Impact factor: 14.819

2.  Pharmacogenetic screening of N-acetyltransferase 2, thiopurine s-methyltransferase, and 5,10-methylene-tetrahydrofolate reductase polymorphisms in Northwestern Mexicans.

Authors:  Marco A Ramos; Rosa E Mares; Erick D Avalos; Anaid Hernández; Rogelio Hernández; Rodrigo Lameda; Analleli E Malváez; Carla A Rodríguez; Rosario Rodríguez
Journal:  Genet Test Mol Biomarkers       Date:  2011-01-22

3.  Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population.

Authors:  J A Agúndez; M Olivera; C Martínez; J M Ladero; J Benítez
Journal:  Pharmacogenetics       Date:  1996-10

Review 4.  Arylamine N-acetyltransferases: what we learn from genes and genomes.

Authors:  Sotiria Boukouvala; Giannoulis Fakis
Journal:  Drug Metab Rev       Date:  2005       Impact factor: 4.518

5.  Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene.

Authors:  H J Lin; C Y Han; B K Lin; S Hardy
Journal:  Pharmacogenetics       Date:  1994-06

6.  Polymorphic N-acetyltransferase (NAT2) in Amerindian populations of Panama and Colombia: high frequencies of point mutation 857A, as found in allele S3/M3.

Authors:  T D Arias; L F Jorge; E U Griese; T Inaba; M Eichelbaum
Journal:  Pharmacogenetics       Date:  1993-12

7.  Arylamine N-acetyltransferases. Expression in Escherichia coli, purification, and substrate specificities of recombinant hamster monomorphic and polymorphic isozymes.

Authors:  C R Wagner; C P Bergstrom; K R Koning; P E Hanna
Journal:  Drug Metab Dispos       Date:  1996-02       Impact factor: 3.922

Review 8.  Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.

Authors:  Edith Sim; Nathan Lack; Chan-Ju Wang; Hilary Long; Isaac Westwood; Elizabeth Fullam; Akane Kawamura
Journal:  Toxicology       Date:  2008-09-12       Impact factor: 4.221

Review 9.  Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.

Authors:  Jason M Walraven; Yu Zang; John O Trent; David W Hein
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

10.  Natural killer cells are recruited during pulmonary tuberculosis and their ex vivo responses to mycobacteria vary between healthy human donors in association with KIR haplotype.

Authors:  Damien Portevin; Laura E Via; Seokyong Eum; Douglas Young
Journal:  Cell Microbiol       Date:  2012-07-30       Impact factor: 3.715

View more
  3 in total

1.  A pilot study of the modulation of sirtuins on arylamine N-acetyltransferase 1 and 2 enzymatic activity.

Authors:  Eneida Turiján-Espinoza; Rául Alejandro Salazar-González; Edith Elena Uresti-Rivera; Gloria Estela Hernández-Hernández; Montserrat Ortega-Juárez; Rosa Milán; Diana Portales-Pérez
Journal:  Acta Pharm Sin B       Date:  2017-12-30       Impact factor: 11.413

2.  NAT2 Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris.

Authors:  Recep Dursun; Hatice Gül Dursun; Ayşe Gül Zamani; Mahmut Selman Yıldırım; İlknur Çınar
Journal:  Biomed Res Int       Date:  2018-06-11       Impact factor: 3.411

3.  Weighted Gene Co-expression Network Analysis Identified a Novel Thirteen-Gene Signature Associated With Progression, Prognosis, and Immune Microenvironment of Colon Adenocarcinoma Patients.

Authors:  Cangang Zhang; Zhe Zhao; Haibo Liu; Shukun Yao; Dongyan Zhao
Journal:  Front Genet       Date:  2021-07-12       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.